Symbols

RANI

Rani Therapeutics·NASDAQ

--(--)

RANI fundamentals

RANI Q4 2025 Earnings

Rani Therapeutics (RANI) released its earnings on Mar 26, 2026: revenue was 1.46M (YoY +42.12%), missed estimates; EPS was -0.07 (YoY +74.07%), missed estimates.

Revenue / YoY

1.46M

+42.12%

EPS / YoY

-0.07

+74.07%

Report date

Mar 26, 2026

RANI Earnings Call Summary for Q4,2025

$1.1B Chugai Collaboration: Validates RaniPill platform scalability with potential expansion to 5+ drug targets.
Phase I Trial Initiated: RT-114 enters clinic with focus on tolerability to differentiate in obesity market.
Strong Cash Position: $49.7M cash runway into 2027, enabling strategic growth without dilution.
Cost Efficiency: 25% YoY R&D expense reduction supports sustainable development.

Earnings

EPS

Revenue

Revenue & Expenses

RANI has released its 2025 Q4 earnings report, with revenue of 1.46M, reflecting a YoY change of 42.12%, and net profit of -9.07M, showing a YoY change of 42.28%. The Sankey diagram below clearly presents RANI's revenue sources and cost distribution.

Key Indicators

Rani Therapeutics (RANI) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Rani Therapeutics (RANI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Rani Therapeutics (RANI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Rani Therapeutics (RANI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown